Table 3.

Nonhematologic treatment-emergent adverse events of all grades reported in ⩾ 10% or grade ⩾ 3 reported in ⩾ 2% of patients in the pooled analysis of single-agent zanubrutinib safety (n = 779). ⁷⁸ .

Adverse event	All-grade, %	Grade ⩾ 3, %
Upper respiratory tract infection	40	2
Rash a	27	0.4
Bruising a	25	0.1
Musculoskeletal pain a	24	2
Diarrhea	23	2
Cough	21	0.1
Pneumonia a	21	11
Urinary tract infection	15	2
Fatigue	15	1
Hematuria	14	0.5
Constipation	14	0.4
Headache	13	1
Pyrexia	13	1
Hypertension	12	5
Nausea	11	0.4
Sepsis a	2	2

^aIncludes multiple preferred terms within the Medical Dictionary for Regulatory Activities.